There is no better place to unlock the full potential of our iconic brands than in the state many of our brands have proudly called home for more than 135 years,” said CEO Thibault Mongon at the debut ...

The 290,000sqft space will consolidate and optimise US consumer health companies teams which had previously been too spread ...

Kenvue (NYSE:KVUE) quickly gained 4% amid some takeover speculation. There's some speculation that Kenvue (NYSE:KVUE), known for making Tylenol, has attracted takeover interest, according to ...

Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs ...

Shortly after Starboard Value pitched four nominees for Kenvue's board of directors, the consumer healthcare company and its activist investor have signed a "cooperation agreement" that sees ...

Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Phil Stewart has reported from more than 60 countries, including Afghanistan, Ukraine, Syria, Iraq, Pakistan, Russia, Saudi Arabia, China and South Sudan. An award-winning Washington-based ...

Kenvue KVUE-0.30%decrease; red down pointing triangle has struck a cooperation agreement with Starboard Value, averting a proxy fight with the activist investment firm. Kenvue on Wednesday said it ...

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), the world’s largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors ...

Kenvue has a one year low of $17.67 and a one year high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Deep-pocketed investors have adopted a bearish approach towards Kenvue (NYSE:KVUE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...